UGN-102 Delivers High 12-Month DOR in Non-Muscle Invasive Bladder Cancer
The phase 3 ENVISION study investigating UGN-102 previously met its primary end point of complete response rate.
Read More
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Listen
FDA Considers Subcutaneous Amivantamab in EGFR-Mutated NSCLC
A biologics license application for subcutaneous amivantamab combined with recombinant human hyaluronidase has been submitted to the FDA for NSCLC indications.
The Future of Breast Cancer Care: Blackwood on Personalized Approaches
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
Phase 3 SunRISe-2 Study Investigates Novel TAR-200 Therapy in Muscle Invasive Bladder Cancer
Stephen Williams, MD, MBA, MS, FACS, FACHE, discussed updates from the SunRISe-2 study investigating TAR-200 plus cetrelimab vs chemotherapy in muscle invasive bladder cancer.
Subcutaneous Atezolizumab Is Equivalent to Intravenous Formulation in NSCLC
Atezolizumab can be given subcutaneously and it is a preferred method of delivery by patients with non–small cell lung cancer, according to results from the phase 2 IMscin002 trial.
